Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris

Completed · Phase 1

Conditions studied: Acne Vulgaris

In brief

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of dapsone in subjects with acne vulgaris following 28 days of dosing.

Key facts

Study ID

NCT01773122

Run by

Allergan

People needed

77

Starts

2013-01-21

Expected to finish

2013-05-05

Last updated by the study team

2019-04-24

Who can join

Age: 16 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of acne vulgaris
• Willing to avoid excessive or prolonged exposure to ultraviolet light (e.g., sunlight, tanning beds) throughout the study
• If male, the subject must agree to shave the facial treatment area and agree to maintain his routine shaving regimen for the duration of the study
• willing to avoid applying moisturizers, sunscreens, cosmetics (except eye and lip makeup), and chemical peels throughout the study

You may not qualify if…

• Oral acne treatments within 6 months

Where it is running

• Study site — College Station, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.